

11 Jan 2022 | News

## **QUOTED.** Michael Mussallem.

by

During the annual J.P. Morgan Healthcare Conferences on 10 January, Edwards Lifesciences CEO Michael Mussallem affirmed previous revenue guidance and discussed plans for 2022.

"We expect [2022] to be a year of significant milestone achievements and a lot of investments in our future." – Michael Mussallem, CEO, Edwards Lifesciences

• Find out more: *JPM 2022: Dexcom, Edwards, J&J, Medtronic, ResMed* 

<u>Click here</u> for a free trial of Medtech Insight